Gilead Statement on Agreement in Texas False Claims Act Matter

Foster City, Calif., October 22, 2026 – Gilead Sciences has reached an agreement to resolve litigation relating to the company’s patient support programs. Gilead expressly denies the allegations which never went to trial, and no judge or jury in this case found that Gilead’s patient support programs violate the law.

In fact, this settlement ensures Texas patients can continue to access the Gilead medicines they rely on. Gilead will continue to make its patient support programs available to patients in Texas and across the United States. The case was brought by Health Choice Advocates, an entity formed to file lawsuits against pharmaceutical companies, and the State of Texas later joined it. The settlement agreement is the result of a compromise on disputed issues of fact and law and is not an admission of facts, wrongdoing or liability by Gilead. Gilead entered into this agreement to avoid the cost and distraction of prolonged litigation.

Gilead believes these programs are lawful, appropriate, beneficial, and consistent with its commitment to patients. The company remains focused on advancing innovative therapies, meeting patient needs and upholding strong compliance standards.

Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).